ANI Pharmaceuticals Inc (ANIP) Cash Flow Statement

A cash flow statement shows the actual cash a company generated and spent across operating, investing, and financing activities over a reporting period.

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally.

Total Cash From Operating Activities Chart for ANI Pharmaceuticals Inc

ANI Pharmaceuticals Inc (ANIP) operating cash flow for FY2025 was USD 185.2M, a 189.3% change from FY2024. ANI Pharmaceuticals Inc's operating cash flow moved from USD -3.0M in 1998 to USD 185.2M in 2025 over 27 years. Operating cash flow compound annual growth rate: 5-year CAGR of 64.7%, 10-year CAGR of 26.8%.

The most recent 3 years are real; the rest is blurred as a preview. Sign up free to unlock every line item, quarterly data, and the real full history. Free account: 8 years of history for 10 flagship companies. Premium: full history for 500+ companies. Premium is €10.00/month. See pricing.

Total Cash From Operating Activities (US Dollars)

R&D as % of Revenue

Key Stats

Market Cap
$1.66B
Implied Share Price
$72.32
Enterprise Value
$1.94B
Revenue (TTM)
$978.38M
EBITDA
$209.41M
Profit Margin
11.07%
Trailing P/E
15.65
Forward P/E
7.12
Price/Book (MRQ)
2.86
Price/Sales (TTM)
1.70
EV/EBITDA
7.94
EV/Revenue
1.99
Dividend Yield
—
Book Value
$27.87
Free Cash Flow (FY2025)
$150.90M
Free Cash Flow Yield
9.09%

Snapshot as of 18th October 2026 — not point-in-time controlled, may lag the live market by a few days.